NDC Package 72607-100-00 Tazverik

Tazemetostat Tablet, Film Coated Oral - View Billable Units, 11-Digit Format, RxNorm

Package Information

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
72607-100-00
Package Description:
240 TABLET, FILM COATED in 1 BOTTLE
Product Code:
Proprietary Name:
Tazverik
Non-Proprietary Name:
Tazemetostat
Substance Name:
Tazemetostat Hydrobromide
Usage Information:
TAZVERIK is indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
11-Digit NDC Billing Format:
72607010000
NDC to RxNorm Crosswalk:
  • RxCUI: 2274384 - tazemetostat 200 MG Oral Tablet
  • RxCUI: 2274384 - tazemetostat 200 MG (equivalent to 228 MG tazemetostat HBr) Oral Tablet
  • RxCUI: 2274390 - TAZVERIK 200 MG Oral Tablet
  • RxCUI: 2274390 - tazemetostat 200 MG Oral Tablet [Tazverik]
  • RxCUI: 2274390 - Tazverik 200 MG (equivalent to 228 MG tazemetostat HBr) Oral Tablet
  • Product Type:
    Human Prescription Drug
    Labeler Name:
    Epizyme, Inc.
    Dosage Form:
    Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
    Administration Route(s):
  • Oral - Administration to or by way of the mouth.
  • Sample Package:
    No
    FDA Application Number:
    NDA211723
    Marketing Category:
    NDA - A product marketed under an approved New Drug Application.
    Start Marketing Date:
    01-23-2020
    Listing Expiration Date:
    12-31-2024
    Exclude Flag:
    N
    Code Structure:

    The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

    * Please review the disclaimer below.

    Frequently Asked Questions

    What is NDC 72607-100-00?

    The NDC Packaged Code 72607-100-00 is assigned to a package of 240 tablet, film coated in 1 bottle of Tazverik, a human prescription drug labeled by Epizyme, Inc.. The product's dosage form is tablet, film coated and is administered via oral form.

    Is NDC 72607-100 included in the NDC Directory?

    Yes, Tazverik with product code 72607-100 is active and included in the NDC Directory. The product was first marketed by Epizyme, Inc. on January 23, 2020 and its listing in the NDC Directory is set to expire on December 31, 2024 if the product is not updated or renewed by the manufacturer.

    What is the 11-digit format for NDC 72607-100-00?

    The 11-digit format is 72607010000. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

    This package code is originally configured in a 5-3-2 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

    10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
    5-3-272607-100-005-4-272607-0100-00